Skip to content

Search

Showing results for "lung disease preterm"

Genome-wide association study of intraocular pressure identifies the GLCCI1/ICA1 region as a glaucoma susceptibility locus

We found a novel association between intraocular pressure and a common variant at 7p21 near to GLCCI1 and ICA1.

Genome-wide association analysis identifies 13 new risk loci for schizophrenia

Common genetic variation has an important role in the etiology of schizophrenia, and larger studies will allow more detailed understanding of this disorder.

Immunization of newborns with bacterial conjugate vaccines

Bacterial conjugate vaccines are based on the principle of coupling immunogenic bacterial capsular polysaccharides to a carrier protein to facilitate the...

Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis

A conditional analysis provided evidence for multiple associations within the HLA-DRB1-HLA-DQA1 region,and a model in which risk differed between three...

All-cause mortality and cancer incidence among adults exposed to blue asbestos during childhood

This study investigated cancer and mortality of adults exposed to blue asbestos as children.

The Kerry M Stokes AC, Chair of Child Health

This prestigious position, named in honour of Mr Kerry M Stokes AC and the enormous contribution he has made to child health research in Western

Free vaccines for pregnant mums see monumental rise in protection for WA babies

New collaborative research involving almost 600,000 pregnant mothers has demonstrated a dramatic increase in uptake of the whooping cough (pertussis) vaccine after identifying just 22 per cent of WA women had the maternal vaccination between 2012 – 2017.

Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024

Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season. 

Modelling the impact of long-acting monoclonal antibody, maternal vaccine and hybrid programs of RSV immunisation in temperate Western Australia

Two RSV immunisations products: a maternal vaccine, Abrysvo, and a long-acting monoclonal antibody, nirsevimab, both designed to prevent RSV illness in infants, have recently become available. Modelling evidence is required to inform how to optimally use these products in immunisation programs to reduce the burden of RSV in young children.